Haemonetics Corporation announced its third quarter and year-to-date fiscal 2025 results, showcasing steady revenue growth and improved profitability. For the third quarter, revenue increased 4% to $349 million, with organic revenue growth of 2%, excluding currency fluctuations and recent acquisitions. Diluted earnings per share (EPS) were $0.74, while adjusted diluted EPS rose to $1.19, reflecting strong operational performance. Year-to-date revenue grew 7% to $1.03 billion, with adjusted diluted EPS reaching $3.32. Operating cash flow for the quarter was $44 million, with free cash flow at $30 million, contributing to a year-to-date operating cash flow of $65 million and free cash flow of $50 million.

CEO Chris Simon highlighted the company’s record third-quarter margins and the success of its long-range plan in driving profitable growth. Haemonetics is gaining market share, leveraging its differentiated technologies, and evolving its portfolio to further expand margins. Despite external market challenges, the company remains confident in its foundation for sustained long-term growth. Haemonetics also updated its fiscal 2025 guidance, reflecting its strong performance and strategic focus on innovation and operational efficiency.